| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
58,750,000 |
| Market
Cap: |
28.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.355 - $0.478 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Sio Gene Therapies is a a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. Co. has three clinical-stage programs: AXO-AAV-GM1 for the treatment of GM1 gangliosidosis; AXO-AAV-GM2 for the treatment of GM2 gangliosidosis (including Tay-Sachs and Sandhoff diseases); and AXO-Lenti-PD for the treatment of Parkinson's disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Meswani Parag V |
Chief Commercial OfficerOffice |
• – – |
2022-01-28 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
33,733 |
|
-59% |
|
| Nassif David W. |
Chief Financial Officer |
• – – |
2021-12-08 |
4 |
D |
$1.42 |
$8,937 |
D/D |
(6,294) |
45,244 |
|
- |
|
| Nassif David W. |
Chief Financial Officer |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
17,534 |
51,538 |
|
- |
|
| Cheruvu Pavan |
Chief Executive Officer |
• • – |
2021-12-08 |
4 |
D |
$1.42 |
$21,135 |
D/D |
(14,884) |
203,109 |
|
- |
|
| Cheruvu Pavan |
Chief Executive Officer |
• • – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
37,567 |
217,993 |
|
- |
|
| Cheruvu Pavan |
Chief Executive Officer |
• • – |
2021-03-23 |
4 |
B |
$2.48 |
$248,180 |
D/D |
100,000 |
180,426 |
2.81 |
-18% |
|
| Nassif David W. |
Chief Financial Officer |
• – – |
2021-03-22 |
4 |
A |
$0.00 |
$0 |
D/D |
15,060 |
34,004 |
|
- |
|
| Cheruvu Pavan |
Chief Executive Officer |
• • – |
2021-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
22,590 |
80,426 |
|
- |
|
| Corcoran Gavin |
Chief R&D Officer |
• – – |
2021-03-17 |
4 |
A |
$0.00 |
$0 |
D/D |
16,001 |
25,792 |
|
- |
|
| Pande Atul |
Director |
– • – |
2020-11-24 |
4 |
B |
$2.34 |
$23,399 |
I/I |
10,000 |
33,370 |
2.1 |
15% |
|
| Cheruvu Pavan |
Principal Executive Officer |
• • – |
2020-07-08 |
4 |
B |
$2.74 |
$102,638 |
D/D |
37,500 |
57,836 |
2.81 |
-22% |
|
| Pande Atul |
Director |
– • – |
2020-07-08 |
4 |
B |
$2.73 |
$27,290 |
I/I |
10,000 |
23,370 |
2.1 |
-22% |
|
| Corcoran Gavin |
Chief R&D Officer |
• – – |
2020-06-12 |
4 |
D |
$3.46 |
$21,490 |
D/D |
(6,211) |
9,791 |
|
- |
|
| Corcoran Gavin |
Chief R&D Officer |
• – – |
2020-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
16,002 |
16,002 |
|
- |
|
| Cheruvu Pavan |
Principal Executive Officer |
• • – |
2020-06-11 |
4 |
D |
$3.09 |
$30,143 |
D/D |
(9,755) |
20,336 |
|
- |
|
| Cheruvu Pavan |
Principal Executive Officer |
• • – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
22,591 |
30,091 |
|
- |
|
| Nassif David W. |
Principal Financial Officer |
• – – |
2020-06-11 |
4 |
D |
$3.25 |
$17,115 |
D/D |
(5,266) |
18,944 |
|
- |
|
| Nassif David W. |
Principal Financial Officer |
• – – |
2020-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,060 |
24,210 |
|
- |
|
| Pande Atul |
Director |
– • – |
2020-03-16 |
4 |
B |
$1.78 |
$17,844 |
I/I |
10,000 |
13,370 |
2.1 |
69% |
|
| Roivant Sciences Ltd. |
10% Owner |
– – • |
2020-02-24 |
4 |
B |
$3.75 |
$19,999,999 |
D/D |
5,333,333 |
18,577,380 |
2.45 |
-34% |
|
| Nassif David W. |
Principal Financial OfficerOff |
• – – |
2019-07-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,150 |
|
- |
|
| Pande Atul |
Director |
– • – |
2019-06-14 |
4 |
B |
$5.22 |
$17,595 |
D/D |
3,370 |
3,370 |
2.39 |
- |
|
| Cheruvu Pavan |
Chief Executive Officer |
• • – |
2019-06-14 |
4 |
B |
$5.21 |
$39,075 |
D/D |
7,500 |
7,500 |
2.81 |
- |
|
| Qvt Financial Investment Cayman Ltd. |
10% Owner |
– – • |
2019-03-18 |
4 |
B |
$1.50 |
$10,000,001 |
I/I |
6,666,667 |
105,952,381 |
1.5 |
- |
|
| Shabet Rose Sharon |
10% Owner |
– – • |
2019-03-18 |
4 |
B |
$1.50 |
$10,000,001 |
I/I |
6,666,667 |
105,952,381 |
1.5 |
- |
|
64 Records found
|
|
Page 1 of 3 |
|
|
